This new Medicare program offers obesity drugs for $50 a month. Here's what you need to know

For years, popular weight loss drugs known as GLP-1s have been financially inaccessible to most older Americans on Medicare, with monthly costs reaching hundreds of dollars. This week marks a significant change with the launch of the Bridge program, a temporary Medicare pilot initiative that creates a new pathway for coverage of obesity medications. The program specifically targets patients meeting certain criteria, including those with a BMI over 35 and individuals with obesity-related health conditions. Under this program, eligible Medicare beneficiaries can now access GLP-1 drugs from pharmaceutical companies Novo Nordisk and Eli Lilly with a copay of just $50 per month. This represents a major policy reversal for Medicare, which has traditionally barred coverage of medications prescribed solely for weight loss and obesity treatment. The program could dramatically expand patient access to these medications and help prevent costly health complications associated with obesity. Industry estimates suggest the Bridge program could eventually reach as many as 20 million new patients, representing substantial market expansion for both drug manufacturers. With more than 69 million Americans currently enrolled in Medicare, officials anticipate that several million beneficiaries will join the Bridge program immediately upon launch. However, the rollout presents operational challenges. The process requires physicians to submit prior authorization requests to verify that patients meet eligibility requirements before coverage is approved. Healthcare providers have expressed concerns that the influx of new patients could strain already busy clinics and pharmacies, with some doctors cautioning that the healthcare system will need patience during the initial rollout period as patients eagerly begin these medications.